- Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
- New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio
- Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cancer types
- Roche launches Elecsys Epstein-Barr Virus (EBV) immunoassay panel to improve EBV infection staging
- Roche’s Evrysdi approved by European Commission as first and only at home treatment for spinal muscular atrophy
- Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
- Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cash
- Roche launches new high throughput configurations for cobas pro integrated solutions to increase testing efficiency
- New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19
- Roche provides update on tominersen programme in manifest Huntington’s disease
More ▼
Key statistics
As of last trade Roche Holding AG (RHO5:BRN) traded at 304.28, 4.23% above its 52-week low of 291.93, set on Oct 30, 2020.
52-week range
Markit short selling activity
Open | 304.28 |
---|---|
High | 304.28 |
Low | 304.28 |
Bid | 304.69 |
Offer | 307.83 |
Previous close | 303.57 |
Average volume | 46.00 |
---|---|
Shares outstanding | 862.56m |
Free float | 721.95m |
P/E (TTM) | 18.74 |
Market cap | 269.64bn CHF |
EPS (TTM) | 16.52 CHF |
Annual div (ADY) | 9.10 CHF |
---|---|
Annual div yield (ADY) | 2.99% |
Div ex-date | Mar 18 2021 |
Div pay-date | Mar 22 2021 |
Data delayed at least 15 minutes, as of Apr 08 2021.
More ▼